权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Centrifuge-free plasma separation consumable for global point of care viral diagnostics

用于全球护理点病毒诊断的免离心血浆分离耗材

基本信息

批准号：
103921
负责人：
金额：
$ 76.28万
依托单位：
GENEDRIVE PLC
依托单位国家：
英国
项目类别：
Collaborative R&D
财政年份：
2017
资助国家：
英国
起止时间：
2017 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=103921
关键词：
Centrifuge free plasma separation consumable

项目摘要

Currently there are no suitable independent PoC methods for processing patient blood samples to provide plasma for medical diagnostic tests. This means analysis is restricted to centralised laboratory facilities and this significantly impacts time to result and subsequent treatment, and cost to the healthcare provider. This project seeks to capitalise on development of a single-use cartridge that can simply process whole blood from a patient finger-prick blood sample to provide plasma for downstream blood borne virus testing. Plasma can be used with Genedrive® diagnostic tests for hepatitis C (HCV), or any other vendor platforms and diagnostic tests that use plasma as a starting sample. Providing a cartridge that can process blood without relying on clinical laboratory equipment, will significantly impact the provision of many molecular diagnostic tests in low resource settings, where the vast majority of infectious disease diagnostics are required. We have established a working prototype for plasma virus separation based on size exclusion where blood cells are trapped and smaller viral particles (eg. HCV) move through a membrane with the plasma. The sensitivity of the single use device is within the ranges required for clinical use. This technology has the opportunity to change the way blood borne viral diagnostics are conducted in decentralised settings in resource limited countries, providing improved patient care and more timely therapy, and ultimately positively impacting on global health challenges in infectious diseases.

目前还没有合适的独立PoC方法来处理患者血液样本，为医学诊断测试提供血浆。这意味着分析仅限于集中的实验室设施，这极大地影响了获得结果的时间和后续治疗，以及医疗保健提供者的成本。该项目旨在利用一次性药筒的开发，该药筒可以简单地处理取自患者手指穿刺血液样本的全血，为下游血液传播病毒检测提供血浆。血浆可用于Genedrive®丙型肝炎（HCV）诊断测试，或任何其他使用血浆作为起始样本的供应商平台和诊断测试。提供一种无需依赖临床实验室设备即可处理血液的药筒，将对资源匮乏环境中许多分子诊断测试的提供产生重大影响，而这些环境需要绝大多数传染病诊断。我们已经建立了一个基于大小排除的血浆病毒分离的工作原型，其中血细胞被捕获，较小的病毒颗粒(例如。丙型肝炎病毒（HCV）随血浆穿过细胞膜。单次使用装置的灵敏度在临床使用所需的范围内。这项技术有机会改变在资源有限的国家的分散环境中进行血源性病毒诊断的方式，提供更好的患者护理和更及时的治疗，并最终对传染病方面的全球卫生挑战产生积极影响。